ASXC Asensus Surgical, Inc.

Asensus Surgical, Inc. (formerly TransEnterix) is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking the Clinical Intelligence to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare.

$3.43  +0.21 (6.52%)
As of 06/14/2021 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Medical Devices
Index country:  USA
Country of incorporation:  USA
IPO date:  11/09/1992
Outstanding shares:  233,186,653
Average volume:  14,923,713
Market cap:   $755,524,756
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    04367G103
ISIN:        US04367G1031
Sedol:      BNVQ2J0
Valuation   (See tab for details)
PE ratio:   -12.44
PB ratio:   3.65
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy